Los Angeles, California

SYMPOSIUM INFORMATION

>General Information
>Faculty
>Program/Schedule
>Accreditation/CME Surveys
>Registration
>Hotel Reservations

 

Supported by:
PIH Health Good Samaritan Hospital
Los Angeles, CA


Affiliated With:
AMERICAN COLLEGE OF CARDIOLOGY



FIFTH ANNUAL SYMPOSIUM

Contemporary Management of
Cardiovascular Disease in Women

April 23, 2022
Omni Los Angeles Hotel
Los Angeles California

IMPORTANT CME CREDIT NOTICE
CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed. Surveys are accessible after logging in with the email address you submitted during registration.

Surveys will be accessible online the day of the symposium and for 3 weeks following. You must complete the process by May 16, 2022 in order to receive your certificate. Certificates will be available online until November 1, 2022 and are printable directly from the website.

ACCREDITATION
This Live activity, 5th Annual Contemporary Management of Cardiovascular Disease in Women, with a beginning date of April 23, 2022 has been reviewed and is acceptable for up to TBD Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (credit hours subject to change)

AMA: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award.

AANPCP: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AAFP Prescribed credit.

ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.

AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPA Category 1 CME credit.

COURSE DESCRIPTION
Heart disease is the leading cause of death in women in the US and accounts for more deaths each year than all other causes combined. The rates of death are even higher in women of racial or ethnic minority. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the risk of heart disease in women and empower them to be advocates for women's cardiovascular health.

This educational symposium will review the current epidemiology of cardiovascular disease in women and examine women-specific cardiovascular issues related to diagnosis and treatment. Cardiovascular disease more common in women will be discussed, including pulmonary arterial hypertension and ischemia without obstructive CAD. The management of cardiovascular complications during pregnancy will be reviewed. The current data and guidelines for lipids and diet will be discussed. State of the art therapies for structural heart disease, including aortic, mitral and tricuspid valves, with an emphasis on gender-specific outcomes, will be included. Gender differences related to atrial fibrillation, congestive heart failure and COVID-19 infection will be reviewed. Finally, the salient cardiovascular trials of 2019, 2020 and 2021 will be summarized with case-based presentations.

The objective of this symposium is to educate healthcare providers on gender-appropriate approaches in prevention, diagnosis and treatment of women with a broad range of cardiovascular diseases.

PROGRAM OBJECTIVES
At the conclusion of this activity, the participants should be able to:

  1. Be aware of the current epidemiology of cardiovascular disease in women.
  2. Review recent major cardiovascular trials and their therapeutic implications for women.
  3. Identify cardiovascular consequences of COVID-19.
  4. Discuss gender differences related to COVID-19 infection.
  5. Understand the current nomenclature and diagnoses of microvascular disease.
  6. Explore the varied treatment options of INOCA and MINOCA.
  7. Review current statistics of diabetes-related cardiovascular disease.
  8. Discuss diabetic therapies that reduce cardiovascular morbidity and mortality.
  9. Review the pathophysiology of pulmonary arterial hypertension.
  10. Discuss the current therapies for pulmonary arterial hypertension.
  11. Identify the most common cardiovascular complications in pregnancy.
  12. Understand the various treatment options for common cardiovascular diagnoses in the pregnant population.
  13. Review contemporary and future dyslipidemia therapies.
  14. Explain the physiology of intermittent fasting.
  15. Discuss the beneficial effects of intermittent fasting on cardiovascular risk.
  16. Recognize gender differences in atrial fibrillation epidemiology.
  17. Identify appropriate management of atrial fibrillation in women.
  18. Discuss the gender specific issues related to heart failure in women.
  19. Know the current guideline directed pharmacologic management for heart failure.
  20. Discuss the gender specific issues related to cardiac devices for heart failure in women.
  21. Know the current guideline directed device management for heart failure.
  22. Be aware of the gender specific outcomes between TAVR and SAVR.
  23. Understand the current indications for TAVR vs SAVR.
  24. Explore the expanding indications and clinical outcomes for MitraClip.
  25. Understand expanding indications for percutaneous treatment of valvular heart disease.
  26. Review recent major cardiovascular trials and their therapeutic implications for women.

NEEDS ASSESSMENT
Heart disease is the leading cause of death in women in the U.S. and accounts for more deaths each year than all of the other causes combined. In women of racial or ethnic minority the rates of death are even higher. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the impact of cardiovascular disease on women and empower them to be advocates for women's cardiovascular health.

TARGET AUDIENCE
This program has been designed to provide primary care physicians, internists, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists and other healthcare providers with the necessary information to increase knowledge and awareness of cardiovascular disease in women with the goal of improving patient care.

CULTURAL AND LINGUISTIC COMPENTENCY AUDIENCE
This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patientís primary language. Cultural and linguistic competency was incorporated into the planning of this activity.

FACULTY DISCLOSURE
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individualís control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity.